Global Tourette Syndrome Market - 2022-2029

Market Overview

Tourette Syndrome Market is expected to grow at a high CAGR 10.5% during the forecasting period (2022-2029).

Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The early symptoms of the disease are typically noticed in childhood, with the average onset age of three and nine years. Tourette syndrome occurs in people from all ethnic groups; males are affected about three to four times more often than females. According to the National Institute of Neurological Disorders and Stroke, it is estimated that 200,000 Americans have the most severe form of Tourette syndrome and as many as one in 100 exhibits milder and fewer complex symptoms such as chronic motor or vocal tics. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the disease experience their worst tic symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.

Market Dynamics

The Tourette syndrome market growth is driven by several factors, such as a rise in awareness campaigns, an increase in research and development, and a robust pipeline.

The growing awareness about Tourette syndrome is pushing the market growth.

Many government and non-government organizations are working towards creating awareness among the population about Tourette syndrome. One of these initiatives is a joint effort by the Tourette Association of America and the Centers for Disease Control and Prevention (CDC) to provide education and awareness on Tourette to various professional audiences, as well as families, individuals, and the general public. The program, recently renamed "Tourette Health and Education Program" (THEP), works to expand how information and education on Tourette's are shared. Other organizations, such as Tourette's Action, are taking support from social media to increase awareness. On Tourette's Awareness Day, the organization asked people to change their profile pictures with a Tourette's Action twibbon or a TSelfie with one eye blinking, as social media is an incredible communication tool. As per the National Institute of Health, the exact incidence of Tourette's syndrome is uncertain and is predicted to affect 1 to 10 in 1,000 children.

The lack of specific medication is hampering the Tourette Syndrome market growth.

Medications do not terminate tics completely, but they can help a few patients with TS in their daily life. Currently, no one medication is best for all people. Most medications prescribed for TS are not approved by the U.S. Food and Drug Administration (FDA) for treating tics.

Industry analysis.

The Tourette syndrome market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, pipeline analysis Etc.

COVID-19 Impact Analysis

For the containment of the COVID-19 infection spread, socializing people was not allowed, which affected the ongoing research activities as most of the research institutes and contract research centers were shut down or were operating on half of their workforce. Furthermore, the socializing restrictions made it difficult for people to seek healthcare support to understand and improve the condition, negatively affecting the global Tourette's syndrome market during the pandemic.

Segment Analysis

Antipsychotic drugs are predicted to command the Tourette syndrome market during the forecast period (2022-2029).

Antipsychotic drugs are expected to hold the largest market share over the forecast period (2022-2029) due to their ability to treat tics to a greater extent thannon-antipsychotic drugs. Antipsychotic drugs were developed for treating schizophrenia, hence the term antipsychotic. These medications work by blocking another chemical in the brain called dopamine, specifically by blocking dopamine receptors, mainly the D2 receptor. Dopamine has been strongly linked with Tourette's syndrome; some of these drugs are the most useful medications for reducing tics. Fluphenazine, haloperidol (Haldol), risperidone (Risperdal), and pimozide (Orap) are the most commonly used antipsychotic drugs for the treatment of Tourette's syndrome. And these medications are reliably quite effective, but they have adverse effects that make other forms of medications and other therapies exist.

Geographical Analysis

The North American region holds the largest market share of the Tourette Syndrome market

North America dominated the Tourette Syndrome market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to high incidences of Tourette syndrome, a highly aware population, advanced healthcare infrastructure, and favorable government initiatives. For instance, One out of 162 children in the U.S. has Tourette's Syndrome, affecting three out of every 1000 children between the ages of 6 and 17. Moreover, the estimation by the Child Development and Disability Branch, Division of Human Development and Disability, the CDC, Atlanta, GA, USA using data from the 2020 U.S. census, estimated that around 350,000-450,000 Americans living with Tourette syndrome and over 1 million have other persistent tic disorders. Furthermore, many government and non-government organizations are working towards raising awareness among the common population, such as The American Academy of Neurology (AAN) is the world's largest association of neurologists and neuroscience professionals, with over 38,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care to Tourette's patients.

Competitive Landscape

Some of the major key players in the market are H. Lundbeck A/S, Emalex Biosciences, Inc., Teva Pharmaceutical Industries Ltd., Therapix Biosciences Ltd., Neurocrine Bioscience Inc., Eli Lilly and Company, Reviva Pharmaceuticals Inc., Bausch Health Companies Inc., Janssen Pharmaceuticals, and Mylan N.V. In the Tourette Syndrome market, H. Lundbeck A/S holds the leadership position due to robust pipeline, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations, and increasing research and development and high investment, contributing to the growth of the Tourette Syndrome market globally. For instance, on November 10, 2021, Emalex Biosciences Announced positive topline results of phase 2b clinical trial of ecopipam for pediatric Tourette syndrome. Also, on 10 February 2021, SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) entered an agreement with Procaps for the development and production of CannAmide and its SCI-110 product candidate

Eli Lilly Company

Overview

Eli Lilly company was founded in 1876 in Indianapolis, Indiana, U.S. and named after Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. It has its products sold in around 125 countries all around the world. Eli Lilly is pursuing bold advancements in medicine and pushing to close the gaps in health care inequality.

Product Portfolio

Eli Lilly's product portfolio for Tourette Syndrome has Strattera (atomoxetine) capsules (10, 18, 25, 40, 60, 80, and 100 mg capsules).

The Tourette syndrome market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.